Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

Newer products boost growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
 
3Q Revenues: $5.2 billion (+5%)

3Q Earnings:  $778.0 million (-3%)

YTD Revenues: $15.5 billion (+6%)

YTD Earnings: $2.0 billion (+2%)

Comments: Newer pharmaceutical products boosted sales in the quarter. Trulicity sales were $243.6 million in the quarter. Cyramza sales were up 43% to $159.0 million. Taltz sales were $32.5 million and Jardiance sales were $47.5 million in the quarter. Humalog sales were down 9% to $640.8 million driven by lower realized prices, partially offset by increased demand. Forteo sales were $391.2 million, up 12%. Humulin revenues increased 2% to $322.0 million in the quarter. Erbitux sales were $184.6 million, up 115%, partially offset by lower volumes for Zyprexa, down 37% to $149.8 million. Animal health sales were $706.2 million, down 9%. Alimta sales were $570.4 million, down 9%. Cialis sales were $588.2 million, up 4%. The company recognized asset impairment, restructuring and other special charges of $45.5 million and $42.4 million in the third quarters of 2016 and 2015, respectively, primarily related to integration and severance costs for Novartis Animal Health.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters